<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350219</url>
  </required_header>
  <id_info>
    <org_study_id>2010-037</org_study_id>
    <nct_id>NCT01350219</nct_id>
  </id_info>
  <brief_title>Stem Cell Educator Therapy in Type 1 Diabetes</brief_title>
  <official_title>Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianhe Stem Cell Biotechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese government fundings</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianhe Stem Cell Biotechnologies Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The translational potential to the clinical applications of cord blood stem cells has
      increased enormously in recent years, mainly because of its unique advantages including no
      risk to the donor, no ethical issues, low risk of graft-versus-host disease (GVHD), rapid
      availability, and large resource worldwide. Human cord blood contains several types of stem
      cells such as the umbilical cord blood-derived multipotent stem cells (CB-SC). CB-SC possess
      multiple biological properties including the expression of embryonic stem (ES) cell
      characteristics, giving rise to different types of cells and immune modulation. Specifically,
      CB-SC can function as an immune modulator that can lead to control of the immune responses,
      which could in turn be used as a new approach to overcome the autoimmunity of Type 1 diabetes
      (T1D) in patients1 and nonobese diabetic (NOD) mice. Here, the investigators develop a novel
      Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of
      Educator therapy in T1D patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autoimmune control</measure>
    <time_frame>30 days post treatment</time_frame>
    <description>Before treatment, test autoimmune-related markers as baseline; After treatment for 30 days, repeat testing autoimmune-related markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>3 months</time_frame>
    <description>Before treatment, test for C-peptide levels as baseline; After treatment, test C-peptide levels on the 3rd month;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of islet beta cell function</measure>
    <time_frame>6 months</time_frame>
    <description>Test for C-peptide levels on the 6th month;
Full evaluation of islet beta cell function after one year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cord blood stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stem Cell Educator</intervention_name>
    <description>For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.</description>
    <arm_group_label>Cord blood stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients were screened for enrollment in the study if both clinical signs and
             laboratory tests meet the diagnosis standards of American Diabetes Association 2010.
             Other key inclusion criteria were presence of at least one autoantibody to the
             pancreatic islet β cells.

        Exclusion Criteria:

          -  Exclusion criteria were any clinically significant diseases in liver, kidney, and
             heart. Additional exclusion criteria were no pregnancy, no immunosuppressive
             medication, no viral diseases or diseases associated with immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Zhao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianhe Stem Cell Biotechnologies Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Zhao, MD, PhD</last_name>
    <phone>630 723 1968</phone>
    <email>yzhaowhl@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huimin Zhou, MD</last_name>
      <email>zhouhuimindoctor@163.com</email>
    </contact>
    <investigator>
      <last_name>Huimin Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Li, MD</last_name>
      <email>T1DMCT@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zhiguang Zhou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Jinan Military Command</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaoshun Jiang, MD</last_name>
      <phone>86 13953104251</phone>
    </contact>
    <investigator>
      <last_name>Zhaoshun Jiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Delgado, MD</last_name>
      <phone>34 985108000</phone>
      <email>delgadoelias@uniovi.es</email>
    </contact>
    <contact_backup>
      <last_name>Jesus Otero, MD</last_name>
      <phone>34 985108778</phone>
      <email>jesus.otero@sespa.princast.es</email>
    </contact_backup>
    <investigator>
      <last_name>Elias Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Otero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.tianhecell.com</url>
    <description>Click here for more information regarding the Stem Cell Educator therapy in clinical trials</description>
  </link>
  <reference>
    <citation>Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.</citation>
    <PMID>22233865</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev. 2010 Dec;10(2):103-7. doi: 10.1016/j.autrev.2010.08.011. Epub 2010 Aug 20. Review.</citation>
    <PMID>20728583</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One. 2009;4(1):e4226. doi: 10.1371/journal.pone.0004226. Epub 2009 Jan 19.</citation>
    <PMID>19156219</PMID>
  </reference>
  <reference>
    <citation>Zhao Y. Stem cell educator therapy and induction of immune balance. Curr Diab Rep. 2012 Oct;12(5):517-23. doi: 10.1007/s11892-012-0308-1. Review.</citation>
    <PMID>22833322</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>November 25, 2013</last_update_submitted>
  <last_update_submitted_qc>November 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianhe Stem Cell Biotechnologies Inc.</investigator_affiliation>
    <investigator_full_name>Yong Zhao, MD, PhD</investigator_full_name>
    <investigator_title>CEO</investigator_title>
  </responsible_party>
  <keyword>Cord blood stem cells</keyword>
  <keyword>Immune modulation</keyword>
  <keyword>Stem cell educator</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Islet beta cell regeneration</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

